April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
POTENTIAL THERAPEUTIC BENEFIT OF MELATONIN IN REFRACTORY CENTRAL SEROUS CHORIORETINOPATHY
Author Affiliations & Notes
  • Jose D Luna Pinto
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Ana L Gramajo
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Gabriel Marquez
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Victor Torres
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Claudio P Juarez
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Ruth Estela Rosenstein
    Ophthalmology, Ctr Privado de Ojos Romagosa-Fndtn VER, Cordoba, Argentina
  • Footnotes
    Commercial Relationships Jose Luna Pinto, None; Ana Gramajo, None; Gabriel Marquez, None; Victor Torres, None; Claudio Juarez, None; Ruth Rosenstein, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6374. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose D Luna Pinto, Ana L Gramajo, Gabriel Marquez, Victor Torres, Claudio P Juarez, Ruth Estela Rosenstein; POTENTIAL THERAPEUTIC BENEFIT OF MELATONIN IN REFRACTORY CENTRAL SEROUS CHORIORETINOPATHY. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6374. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR).

Methods: Prospective comparative case series.A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d, and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical Coherence Tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes.

Results: At one month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, p<0.05). All patients showed a mean significant reduction (p<0.01) of central macular thickness (CMT) when compared to the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at one month follow-up. No significant side effects were observed. No changes on BCVA or CMT were noted in the control group.

Conclusions: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, since it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable

Keywords: 451 chorioretinitis • 585 macula/fovea • 590 melatonin  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×